This program is supported by an independent educational grant from Lilly.
Originally presented at the 26th World Congress of Psychiatry, Stockholm, Sweden, 25 September 2026
Watch this in:
Revisit this expert-led symposium with Nestor Szerman, Amandine Luquiens, and Khaled Moussawi, exploring practical approaches to identifying, treating, and coordinating care for people with alcohol use disorder (AUD).
Through a longitudinal patient case, the symposium follows three key clinical decision points—from recognizing and diagnosing AUD to developing an individualized treatment plan and coordinating ongoing care.
What will you explore?
- Identify and diagnose AUD — recognize presentations that may be overlooked, use validated screening tools, and distinguish screening from diagnostic assessment and severity classification.
- Align treatment with patient goals — explore patient-centered approaches to treatment goals and consider how pharmacological and behavioral interventions can be integrated into care.
- Coordinate care across services — examine how psychiatrists, addiction specialists, behavioral therapists, primary care, and community support can work together around a shared care plan.
- Monitor and adapt treatment — consider how alcohol use, craving, mood, functioning, treatment response, and safety can inform ongoing management and escalation of care.
Revisit the symposium
Explore the clinical decisions, evidence, and practical strategies discussed at WCP 2026, and consider how these approaches could be applied in your own practice.
Prefer to read? See our Key Clinical Summary here in your preferred language:
Faculty
Néstor Szerman, MD
Dr Néstor Szerman is a psychiatrist and expert in addiction and dual disorders. He is Head of the “Retiro” Mental Health Service at Gregorio Marañón University Hospital in Madrid and Advising Psychiatrist for Alcoholism and Dual Disorders within Madrid Public Mental Health. He is Associate Professor in Drug Dependence at Complutense University of Madrid and has contributed to international guidelines and consensus recommendations on addictive disorders, including alcohol use disorder and opioid use disorder. His clinical and research interests focus on addiction and co-occurring psychiatric disorders.
Amandine Luquiens, MD PhD
Professor Amandine Luquiens is a psychiatrist and addiction specialist at the University of Montpellier and Nîmes University Hospital, France. She holds a PhD in Cognitive Sciences, with her doctoral research focused on quality of life in alcohol use disorder (AUD).
Her clinical and research work focuses on AUD, patient-centred approaches to addiction care, quality of life, early detection, and innovative psychological interventions. She has published extensively on alcohol-related outcomes and treatment, including harm-reduction approaches and emerging therapies for AUD.
Khaled Moussawi, MD, PhD
Dr Khaled Moussawi is an Associate Professor of Neurology and Psychiatry at the University of California, San Francisco (UCSF) and holds the Howard L. Fields Endowed Chair in Pharmacology of Addiction. His research focuses on the neurobiology of substance use disorders and developing novel neuromodulation approaches to treat addiction.
His work includes research into alcohol use disorder (AUD), including the use of transcranial focused ultrasound and deep brain stimulation to target neural circuits involved in craving and alcohol-seeking behaviours. He is Principal Investigator of clinical studies investigating neuromodulation approaches for AUD.
Disclosures
In accordance with EBAC® guidelines, all speakers and moderators participating in this program have declared or indicated any potential conflicts of interest that could bias their presentations. The Organizing Committee/Course Director is responsible for ensuring that all potential conflicts of interest relevant to the event are disclosed to the audience before the start of the continuing education activities.
Partners for Advancing Clinical Education (Partners) requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. All relevant financial relationships are mitigated according to Partners policies.
All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated according to Partners policies. Others involved in the planning of this activity have no relevant financial relationships.
Néstor Szerman, MD, has disclosed financial interests or relationships within the past 24 months with the following ineligible companies:: Advisor for Eli Lilly, Consultant for Eli Lilly, Grant/Research Support from Gidoen Richter, Recordati, Speaker for Gidoen Richter, Recordati. Nestor Szerman MD does intend to reference unlabeled or unapproved uses of products during the presentation.
Amandine Luquiens, MD PhD has disclosed financial interests or relationships within the past 24 months with the following ineligible companies: Advisor for Johnson and Johnson and Camrus, Consultant for Johnson and Johnson and Camrus, Speaker for Johnson and Johnson and Camrus. Amandine Luquiens, MD PhD, does intend to reference unlabeled or unapproved uses of products during the presentation.
Khaled Moussawi, MD, PhD has disclosed financial interests or relationships within the past 24 months with the following ineligible companies: Advisor for Ely Lilly, Consultant for Eli Lilly, Speaker for Eli Lilly. Khaled Moussawi, MD, PhD, does intend to reference unlabeled or unapproved uses of products during the presentation.
Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (Partners) and MedAll. Partners is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Continuing Education
Partners designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physician Associate Continuing Education
Partners has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.
Nursing Continuing Professional Development
The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 1.0 ANCC contact hours.
Pharmacy Continuing Education
Partners designates this continuing education activity for 1.0 contact hour(s) (0.1 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number - JA4008073-9999-26-323-H01-P
Type of Activity: Knowledge
For Pharmacists: Upon successfully completing the post-test with a score of 75% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
EBAC® CME Information:
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the European Board for Accreditation of Continuing Education for Health Professionals (EBAC)
MedAll is an EBAC accredited provider since 2025. The European Board for Accreditation of Continuing Education for Health Professionals (EBAC) accredits Continuing Education (CE) programmes for the international medical community.
This program is accredited by the European Board for Accreditation of Continuing Education for Health Professionals (EBAC®) for one hour of effective education time.
In compliance with EBAC guidelines, all speakers/ chairpersons participating in this programme have disclosed or indicated potential conflicts of interest which might cause a bias in the presentations. The Organizing Committee/Course Director is responsible for ensuring that all potential conflicts of interest relevant to the event are declared to the audience prior to the CE activities.
EBAC® holds an agreement on mutual recognition of substantive equivalency with the US Accreditation Council for CME (ACCME) and the Royal College of Physicians and Surgeons of Canada, respectively.
Through an agreement between the European Board for Accreditation of Continuing Education for Health Professionals (EBAC®) and the American Medical Association, physicians may convert EBAC® External CME credits to AMA PRA Category 1 Credits. Information on the process to convert EBAC® credit to AMA credit can be found on the AMA website. Other healthcare professionals may obtain from the AMA a certificate of participation in an activity eligible for conversion of credit to AMA PRA Category 1 Credit.
The Accreditation Council for Continuing Medical Education (ACCME) and the Royal College of Physicians and Surgeons of Canada hold an agreement on substantial equivalency of accreditation systems with EBAC.
EBAC® is a member of the International Academy for CPD Accreditation (IACPDA) and a partner member of the International Association of Medical Regulatory Authorities (IAMRA).
How to Obtain Your EBAC® CME Credit:
To obtain your CME credit and acquire your certificate, please engage with the activity and complete the evaluation at the end. You will receive a link to your certificate after completing the evaluation.
Fee Information
There is no fee for this educational activity.
This continuing education activity is active starting October 2nd 2026, and will expire on September 25th 2027.